Worcester-based Hanover Insurance Group reported a profit of $89.9 million for the fourth quarter, ending what president and CEO Frederick H. Eppinger called “a strong year for our company.”
Preeclampsia is a leading cause of maternal and infant death worldwide, though the causes are poorly understood, and treatment options are limited.
When an expectant mother develops the disease – which causes high blood pressure, swelling, headache, vision changes and seizures – the normal course of action is to deliver the baby as soon as possible to avoid the potential death of both mother and baby. But when it occurs too early in a pregnancy, that remedy is surrounded by health risks for the baby that could result in life-long problems.
It's a conundrum rEVO Biologics of Framingham is trying to solve. The biopharmaceutical company, which is focused on developing and commercializing treatments for patients with rare, life-threatening diseases, began clinical trials last summer on a drug that may allow women to prolong their pregnancies than what available medicine allows.
Tennessee-based Unum Group has promoted its chief financial officer, Richard McKenney, to succeed retiring CEO Thomas Watjen, the employee-benefits provider announced Tuesday.
A former Telegram and Gazette employee is looking to online fundraiser KickStarter to fund a Worcester newspaper that will be available online and in print.
Researchers at University of Massachusetts Medical School and Worcester Polytechnic Institute, helped by a $2 million grant from the National Institutes of Health, are developing a smartphone app that will help users better understand why they overeat.
Here we go again! Less than a week after a monster blizzard dropped about three feet of snow on Central Massachusetts – including a record in Worcester – the region was braced for another foot or so of snow today as schools canceled classes and many workers decided to stay home.
Life sciences firm AbbVie, which has operations in Worcester, saw a nearly 9-percent increase in fourth-quarter revenue, helped by double-digit growth in its popular arthritis drug, Humira.